Organon & Co.

Organon & Co. has achieved a new 52-week high of USD 13.60, rebounding from a low of USD 5.69. Despite a challenging year with a 34.67% decline, the company maintains a market cap of USD 1,520 million, a P/E ratio of 3.00, and a dividend yield of 1.02%.

Organon & Co. has achieved a new 52-week high of USD 13.49, rebounding from a low of USD 5.69. Despite a challenging year with a 34.96% decline, the company maintains a market cap of USD 1,520 million and a high return on equity of 69.90%.

Organon & Co. has achieved a new 52-week high, marking a recovery from its previous low. Despite a challenging year with a notable performance decline, the company maintains a market capitalization of USD 1,520 million, a high return on equity, and offers a dividend yield appealing to investors.

Organon & Co. has achieved a new 52-week high, marking a recovery from its previous low. Despite this milestone, the company has faced a challenging year, with a significant decline in performance compared to the broader market. Key financial metrics indicate potential undervaluation and highlight its market position.

Organon & Co. has achieved a new 52-week high of USD 13.38, recovering from a low of USD 5.69. Despite this milestone, the company has faced a challenging year, with its stock down significantly compared to the S&P 500. Its market cap is USD 1,650 million, with a low P/E ratio and a high debt-to-equity ratio.

Organon & Co. has seen notable stock activity, with significant gains over the past week and month, outperforming the S&P 500 year-to-date. Despite a low debt-to-equity ratio and high return on equity, the company faces challenges with declining net profit and inventory turnover, indicating underlying pressures.

Organon & Co. has seen notable trading activity, with a significant intraday high reached recently. The company has demonstrated strong monthly and year-to-date performance, despite longer-term declines. With a low debt-to-equity ratio and healthy sales growth, it continues to attract attention in the pharmaceuticals sector.

Organon & Co. experienced a notable stock surge today, significantly outperforming the S&P 500. Over the past month, the company has shown impressive growth, despite facing challenges such as a declining net profit and rising raw material costs. Its valuation remains attractive, with a high return on equity.

Organon & Co., a small-cap pharmaceutical company, has adjusted its valuation, with its stock price rising to $11.26. Over the past year, it has seen a stock return of -7.1%, contrasting with the S&P 500's 30.64%. Key metrics include a P/E ratio of 2.85 and a dividend yield of 0.94%.

Organon & Co. has recently revised its evaluation amid fluctuating market conditions, with its stock price rising significantly. The company has shown strong short-term returns but faces challenges in the longer term, reflecting a mixed outlook across various technical indicators and significant volatility over the past year.

Organon & Co. saw notable trading activity on April 9, 2026, with a significant intraday high. The stock's recent performance has outpaced the S&P 500 over one day and one week, but it faces challenges with a substantial decline over the past year. The company is categorized as a small-cap in the Pharmaceuticals & Biotechnology sector.

Organon & Co. has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company faces difficulties, including a drop in net profit and low inventory turnover, while its market capitalization and P/E ratio indicate a low valuation relative to earnings.

Organon & Co. has reached a new 52-week low, experiencing a significant decline in stock performance over the past year. The company, with a market capitalization of USD 1,650 million, faces challenges including low return on equity, declining net profit, and rising raw material costs, indicating a tough market environment.

Organon & Co. has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company has a market capitalization of USD 1,650 million and a low P/E ratio. Financial metrics indicate a drop in net profit and rising raw material costs, highlighting ongoing difficulties.

Organon & Co., a small-cap pharmaceutical company, has faced significant challenges, experiencing a 57.8% decline over the past year. Currently priced at $6.33, the stock shows bearish indicators, with fluctuations between a 52-week high of $15.88 and a low of $6.18, reflecting a cautious market environment.

Organon & Co. has faced significant challenges, with its stock price declining notably and a substantial drop in net profit over the latest quarter. Despite a long-term growth rate in net sales, inefficiencies in inventory management and a decrease in operating profit highlight ongoing struggles in the company's market performance.

Organon & Co. has hit a new 52-week low, reflecting a challenging year with a significant stock price decline. The company has a market capitalization of USD 2,722 million, a low P/E ratio, and a high return on equity, but faces operational difficulties and increased costs.

Organon & Co. has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company has a market capitalization of USD 2,722 million, a low P/E ratio, and reports a decrease in net profit alongside rising raw material costs, indicating ongoing financial struggles.

Organon & Co., a small-cap pharmaceutical company, is experiencing stock price fluctuations, currently at $10.57. The company has faced significant challenges, with a year-over-year return of -45.77%, underperforming the S&P 500. Technical indicators present a mixed outlook, reflecting varied momentum in the market.